Ellen R. Strahlman, a director at Altria Group, Inc., executed a sale of 2,000 shares of the company's common stock on May 26, 2026. The total value realized from this transaction was $145,118.
The divestment involved multiple sales transactions, with the weighted average price calculated at $72.559 per share. These individual sales occurred across a narrow range of prices, specifically between $72.50 and $72.61 per share. It is noteworthy that, as of the time of reporting, Altria stock was trading at $72.07, reflecting substantial gains for the equity over the preceding six months, amounting to 26.5%.
Following this recent sale, Ms. Strahlman retains a holding of 25,102 shares of Altria Group common stock. These remaining shares are categorized as deferred stock held within the Stock Compensation Plan for Non-Employee Directors.
The company's financial profile includes an established dividend yield of 5.88% and a long history of shareholder returns, having maintained consistent dividend payments for 56 consecutive years. Furthermore, analysis from InvestingPro suggested that Altria appeared to be undervalued at its current market levels.
Beyond the insider transaction, recent corporate news provided several updates on Altria Group's operational and financial standing. The company recently disclosed first-quarter adjusted earnings per share of $1.32, a figure that surpassed the consensus estimate of $1.25. This strong performance was supported by revenue figures that exceeded expectations by 4%. Furthermore, the gross margin also outperformed forecasts, beating projections by 90 basis points, which contributed to operating income posting at 5% above the established consensus.
These positive financial results prompted an adjustment from Morgan Stanley, which increased its price target for Altria to $71 while maintaining an Equalweight rating on the stock. On a related operational note, Altria's subsidiary, U.S. Smokeless Tobacco Company, announced plans for a facility consolidation. Specifically, the Nashville, Tennessee manufacturing site will be closed, with operations slated to transition to Hopkinsville, Kentucky by early 2028.
In terms of corporate governance and leadership, Altria also confirmed executive changes, naming Salvatore Mancuso as the new Chief Executive Officer. Mr. Mancuso's compensation package is detailed, including an annual base salary set at $1,350,000, supplemented by various stock units and incentive awards.
From a regulatory perspective, developments were noted regarding the U.S. Food and Drug Administration (FDA). The FDA updated its enforcement priorities for tobacco products, which contributed to an increase in Altria's stock value, alongside other companies within the sector. This new guidance issued by the FDA specifically pertains to both eVapour products and oral nicotine pouches that are currently undergoing scientific review.
Key Takeaways and Market Implications
- Regulatory risk remains a factor, highlighted by the FDA's updated enforcement priorities concerning eVapour products and oral nicotine pouches.
- The ongoing changes in leadership structure, such as the appointment of Salvatore Mancuso, represent internal transitions that require monitoring.
- Facility consolidation presents logistical and operational uncertainties for U.S. Smokeless Tobacco Company.